Abstract
The efficiency of methotrexate use in the basic therapy of rheumatoid arthritis is limited because of risk of side effects and fast drug efflux from zone of joints as well. We have developed a new stabilized form of methotrexate using phospholipid micelles of the injection form of the Phosphogliv preparation as a carrier. Phosphogliv has recently been developed in the Institute of Biomedical Chemistry (Moscow), as the emulsion of 50 nm phospholipid nanoparticles stabilized by glycyrrhizic acid. The conditions of maximal methotrexate incorporation into the phospholipid nanoparticles were optimized under control of HPLC (60% of total methotrexate was associated with nanoparticles). Methotrexate in phospholipid nanoparticles exhibited higher therapeutic efficiency in experimental adjuvant arthritis in rats than with free methotrexate. (This was evaluated by the decrease of edema and swelling of joints and inhibition of secondary inflammatory reaction.) The increase of antirheumatic activity of the developed preparation may also be attributed to the influence of glycyrrhizic acid, possessing both anti-inflammatory and immune properties. It is suggested to use a new form of methotrexate for intra-articular administration for rheumatoid arthritis treatment.
Similar content being viewed by others
References
Couvreur, P and Vauthier, C., Pharm. Res., 2006, vol. 23, pp. 1417–1450.
Yih, T.C. and Al-Fandi, M., J. Cell Biochem., 2006, vol. 97, pp. 1184–1190.
Drummond, D., Meyer, O., Hong, K., Kirpotin, D., and Papahadjopoulos, D., Pharmacol. Rev., 1999, vol. 51, pp. 691–743.
Dolhain, R.I., Talk, P.P., Dijkmans, B.A., De Kuiper, P., Breedveld, F.C., Miltenburg, A.M., Br. J. Rheumatol., 1998, vol. 37, pp. 502–508.
Kukowska-Latallo, J.F., Candido, K.A., Cao, Z., Nigavekar, S.S., Majoros, I.J., Thomas, T.P., Balogh, L.P., Khan, M.K., and Baker, J.R., Cancer Res., 2005, vol. 65, pp. 5317–5324.
Vodovozova, E.L., Evdokimov, D.V., and Molotkovskii, Yu.G., Bioorgan. Khim., 2004, vol. 30, pp. 663–665.
Ioffe, V., Kalendarev, T., Rubinstein, I., Zabetski, R., and Zupkovitz, G., J. Chromatogr A, 2004, vol. 1031, pp. 249–258.
Gao, K. and Jiang, X., Int. J. Pharm., 2006, vol. 310, pp. 213–219.
Kohler, N., Sun, C., Wang, J., and Zhang, M., Langmuir, 2005, vol. 21, pp. 8858–8864.
Chau, Y., Tan, F.E., and Langer, R., Bioconjug. Chem., 2004, vol. 15, pp. 931–941.
Ruckmani K., Sivakumar M., and Ganeshkumar P.A., J. Nanosci. Nanotechnol., 2006, vol. 6, pp. 2991–2995.
Nasonov E.L., Karateev, D.E., Chichasova, N.V., and Chemeris, N.A., Klin. Farmakol. Ther, 2005 no. 1, pp. 72-75
Omata, T., Segawa, Y., Inoue, N., Tsuzuike, N., Itokazu, Y., and Tamaki, H., Res. Exp. Med. (Berl.), 1997}, vol. 197, pp. 81–90.
Schuerwegh, A.J., van Offel, J.F., Bridts, C.H., Stevens, W.J., and De Clerck, L.S., J. Rheumatol., 2001, vol. 28, pp. 1793–1799.
Suzuki, Y., Nakagawa, M., Masuda, C., Ide, M., Uehara, R., Ichikawa, Y., and Mizushima, Y., J. Rheumatol., 1997, vol. 24, pp. 1890–1895.
Groff, G.D., Shenberger, K.N., Wilke, W.S., and Taylor, T.H., Semin. Arthritis Rheum., 1983, vol. 12, pp. 333–347.
Davydenkova, E.F., Ternova, N.K., Rozenberg, O.A., Noskin, L.A., and Loshakova, L.V., Byul. Eksper Biol. Med., 1984, vol. 97, pp. 656–658.
Bonanomi, M.H., Velvart, M., Stimpel, M., Roos, K.M., Fehr, K., and Weder, H.G., Rheumatol. Int., 1987, vol. 7, pp. 203–212.
Foong, W.C. and Green, K.L., J. Pharm. Pharmacol., 1993, vol. 45, pp. 204–209.
Kim, M.M., Lee, S.H., Lee, M.G., Hwang, S.J., and Kim, C.K., Biopharm. Drug Dispos., 1995, vol. 16, pp. 279–293.
Williams, A.S., Camilleri, J.P., Goodfellow, R.M., and Williams, B.D., Br. J. Rheumatol., 1996, vol. 35, pp. 719–724.
Archakov, A.I., Sel’tsovskii, A.P., Lisov, V.I., Tsyganov, D.I., Knyazhev, VA., Ipatova, O.M., and Torkhovskaya, T.I., Vopr Med. Khim., 2002, vol. 48, pp. 139–151.
Ipatova, O.M., Fosfogliv: mekhanism deistviya i primenenie v klinike (Phosphogliv: Mechanism of Action and Clinical Application), Academician of RAMS A.I. Archakov, Ed., Moscow: Institute of Biomedical Chemistry, RAMS, 2005.
A Medicinal Preparation and Mode of Treatment of Rheumatoid Diseases, Patent Application no. 2006114078, Priority Date April 26, 2006.
Fuchs, B., Schiller, J., Wagner, U., Hantzschel, H., and Arnold, K., Clin. Biochem., 2005, vol. 38, pp. 925–933.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © M.G. Zykova, V.N. Prozorovskii, O.M. Ipatova, T.I. Torkhovskaya, V.V. Glazatov, 2008, published in Biomeditsinskaya Khimiya.
Rights and permissions
About this article
Cite this article
Zykova, M.G., Prozorovskii, V.N., Ipatova, O.M. et al. Antirheumatic activity of methotrexate in phospholipid nanoparticles (Phosphogliv). Biochem. Moscow Suppl. Ser. B 2, 71–74 (2008). https://doi.org/10.1007/s11828-008-1007-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11828-008-1007-y